Aisthesis Medical, a UK-based healthtech startup developing hospital-grade AI clinical decision support software, today announced the successful closing of a £900k pre-seed funding round led by Twin Path Ventures with participation from TECS Capital. The funding will accelerate the development and regulatory clearance of VIOSync SPI, an AI-powered platform that predicts in-hospital sepsis development within the next 48 hours.
Sepsis is one of the world’s most urgent healthcare challenges, causing over 11 million deaths each year and costing healthcare systems billions. Early detection and timely intervention are critical, yet frontline clinicians often lack the tools to identify the onset of sepsis before deterioration occurs.
VIOSync Sepsis Prediction Index (SPI) addresses this need by securely ingesting multimodal patient data from hospital systems to create a digital twin of the patient’s evolving physiology. Using explainable AI algorithms, the platform predicts the onset of sepsis within 48 hours, providing clinicians with transparent risk drivers and actionable insights to intervene earlier and save lives.
This investment will support Aisthesis Medical’s mission to empower clinicians with trusted, explainable AI tools that prevent life-threatening patient deterioration. Funds will be used to advance CE MDR submission for VIOSync SPI, expand clinical validation studies across leading hospitals in the UK and EU, and strengthen the team ahead of NHS and international pilot deployments.
